TRILLIUM THERAPEUTICS INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2021-10-28: Study NCT05139225; Company role Collaborator; Phase Phase 1; Status Completed.
- 2012-03: Study NCT01559961; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2021-10-28 | NCT05139225 A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma | Collaborator Lead: Memorial Sloan Kettering Cancer Center | Phase 1 | Completed | Multiple Myeloma | 7 | 2026-07-01 |
| 2012-03 | NCT01559961 Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome | Lead sponsor | Phase 1 | Completed | Interstitial Cystitis | 28 | 2013-06 |